Core Laboratories（CLB）株式概要
コアラボラトリーズ社は、米国内外の石油・ガス業界に貯留層特性と生産性向上に関するサービスと製品を提供している。 詳細
CLB Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Core Laboratories Inc. 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$14.54 |
| 52週高値 | US$20.36 |
| 52週安値 | US$9.72 |
| ベータ | 1.0 |
| 1ヶ月の変化 | -16.68% |
| 3ヶ月変化 | -17.01% |
| 1年変化 | 29.47% |
| 3年間の変化 | -34.27% |
| 5年間の変化 | -64.93% |
| IPOからの変化 | 384.67% |
最新ニュース
ナラティブの更新 • May 23
CLB: Middle East Disruptions Will Shape Undervalued Shares And Future P/E
Analysts have kept their $22.00 price target for Core Laboratories unchanged, citing updated assumptions that include a slightly higher discount rate and revenue growth outlook, along with a marginally lower profit margin and P/E expectation. What's in the News Core Laboratories revised its first quarter 2026 guidance, now expecting revenue between US$119,000,000 and US$123,000,000, operating income ex-items of US$5,700,000 to US$7,100,000, and EPS ex-items of US$0.05 to US$0.07, citing impacts from geopolitical conflict in the Middle East, client project delays, travel limits, and supply chain disruptions (Key Developments).
ナラティブの更新 • Apr 28
CLB: Fair Outlook Balances Middle East Disruptions And Governance Changes
Analysts have raised their price target on Core Laboratories from about $14.00 to roughly $16.33, citing updated views on fair value, discount rate, revenue growth, profit margins, and future P/E assumptions. What's in the News Core Laboratories revised its first quarter 2026 earnings guidance, citing client driven project delays, travel constraints, and supply chain disruptions linked to geopolitical conflict in the Middle East, and now expects revenue of US$119,000,000 to US$123,000,000 and EPS, ex items, of US$0.05 to US$0.07 for the period (Key Developments).ナラティブの更新 • Apr 14
CLB: Fair Value View Will Rely On Middle East Risk And P/E Assumptions
Analysts have raised their price target on Core Laboratories from $18 to $22, citing updated assumptions around revenue growth, profit margins, and a slightly higher future P/E multiple as key drivers of the change. What's in the News Core Laboratories revised its first quarter 2026 earnings guidance, citing client driven project delays, travel constraints, and supply chain disruptions linked to geopolitical conflict in the Middle East, and now expects revenue of US$119,000,000 to US$123,000,000, operating income ex items of US$5,700,000 to US$7,100,000, and Earnings Per Share ex items of US$0.05 to US$0.07 (Key Developments).Seeking Alpha • Mar 26
Core Laboratories: Profit Margins Are Too Small To Get Excited About
Summary Core Laboratories remains a HOLD due to persistently low profit margins and unattractive free cash flow yields. Recent Middle East disruptions have significantly impacted CLB’s higher-margin Reservoir Description segment, prompting a downward revision of Q1 EPS guidance. CLB’s capital allocation will continue with a 50/50 split between debt reduction and shareholder returns, targeting leverage below 1.0x. The current valuation at 14x EBITDA is not justified given flat revenues, low margins, and increased operational risks. The stock is valued at low single digit free cash flow yields. Read the full article on Seeking AlphaRecent updates
ナラティブの更新 • May 23
CLB: Middle East Disruptions Will Shape Undervalued Shares And Future P/E
Analysts have kept their $22.00 price target for Core Laboratories unchanged, citing updated assumptions that include a slightly higher discount rate and revenue growth outlook, along with a marginally lower profit margin and P/E expectation. What's in the News Core Laboratories revised its first quarter 2026 guidance, now expecting revenue between US$119,000,000 and US$123,000,000, operating income ex-items of US$5,700,000 to US$7,100,000, and EPS ex-items of US$0.05 to US$0.07, citing impacts from geopolitical conflict in the Middle East, client project delays, travel limits, and supply chain disruptions (Key Developments).ナラティブの更新 • Apr 28
CLB: Fair Outlook Balances Middle East Disruptions And Governance Changes
Analysts have raised their price target on Core Laboratories from about $14.00 to roughly $16.33, citing updated views on fair value, discount rate, revenue growth, profit margins, and future P/E assumptions. What's in the News Core Laboratories revised its first quarter 2026 earnings guidance, citing client driven project delays, travel constraints, and supply chain disruptions linked to geopolitical conflict in the Middle East, and now expects revenue of US$119,000,000 to US$123,000,000 and EPS, ex items, of US$0.05 to US$0.07 for the period (Key Developments).ナラティブの更新 • Apr 14
CLB: Fair Value View Will Rely On Middle East Risk And P/E Assumptions
Analysts have raised their price target on Core Laboratories from $18 to $22, citing updated assumptions around revenue growth, profit margins, and a slightly higher future P/E multiple as key drivers of the change. What's in the News Core Laboratories revised its first quarter 2026 earnings guidance, citing client driven project delays, travel constraints, and supply chain disruptions linked to geopolitical conflict in the Middle East, and now expects revenue of US$119,000,000 to US$123,000,000, operating income ex items of US$5,700,000 to US$7,100,000, and Earnings Per Share ex items of US$0.05 to US$0.07 (Key Developments).Seeking Alpha • Mar 26
Core Laboratories: Profit Margins Are Too Small To Get Excited About
Summary Core Laboratories remains a HOLD due to persistently low profit margins and unattractive free cash flow yields. Recent Middle East disruptions have significantly impacted CLB’s higher-margin Reservoir Description segment, prompting a downward revision of Q1 EPS guidance. CLB’s capital allocation will continue with a 50/50 split between debt reduction and shareholder returns, targeting leverage below 1.0x. The current valuation at 14x EBITDA is not justified given flat revenues, low margins, and increased operational risks. The stock is valued at low single digit free cash flow yields. Read the full article on Seeking Alphaナラティブの更新 • Jan 26
CLB: Fair Value View Will Rely On Stable Margins And P/E Assumptions
Analysts held their price target on Core Laboratories steady at US$18.00, citing only small tweaks to inputs such as discount rate, revenue growth, profit margin and future P/E assumptions, rather than any major shift in their overall view of the company. Valuation Changes Fair Value: Held steady at US$18.00, indicating no change in the core valuation output.ナラティブの更新 • Jan 11
CLB: Fair Value View Will Rely On Stabilizing Margins And EPS
Analysts kept their Core Laboratories fair value estimate around $18.00. The updated price target mainly reflects slightly adjusted assumptions for discount rate, revenue growth, profit margin, and future P/E rather than a major shift in their view of the stock.ナラティブの更新 • Dec 14
CLB: Future Earnings And Margins Are Expected To Gradually Stabilize
Analysts have modestly reduced their price target on Core Laboratories by 1 dollar to 18 dollars. This reflects a slightly lower fair value despite improved expectations for revenue growth, profit margin, and a less demanding future price to earnings multiple.分析記事 • Nov 21
A Look At The Fair Value Of Core Laboratories Inc. (NYSE:CLB)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Core Laboratories fair value estimate is US$14.45 Core...ナラティブの更新 • Sep 10
Middle East And Asia Pacific Markets Will Secure Energy Success
With both the discount rate and future P/E ratio remaining essentially stable, the consensus analyst price target for Core Laboratories was unchanged at $14.00. What's in the News Core Laboratories issued third quarter 2025 guidance, expecting revenue of $127.5–134.5 million, operating income of $13.6–16.2 million, operating margin of approximately 11%, and EPS of $0.18–0.22.分析記事 • Sep 10
Core Laboratories Inc.'s (NYSE:CLB) 25% Jump Shows Its Popularity With Investors
Core Laboratories Inc. ( NYSE:CLB ) shareholders would be excited to see that the share price has had a great month...分析記事 • Jul 24
We Think Core Laboratories (NYSE:CLB) Is Taking Some Risk With Its Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...分析記事 • Jul 03
Core Laboratories (NYSE:CLB) Will Be Hoping To Turn Its Returns On Capital Around
When it comes to investing, there are some useful financial metrics that can warn us when a business is potentially in...分析記事 • Jun 12
Is There An Opportunity With Core Laboratories Inc.'s (NYSE:CLB) 49% Undervaluation?
Key Insights The projected fair value for Core Laboratories is US$23.89 based on 2 Stage Free Cash Flow to Equity Core...分析記事 • Apr 04
Core Laboratories Inc.'s (NYSE:CLB) Price In Tune With Earnings
With a price-to-earnings (or "P/E") ratio of 20x Core Laboratories Inc. ( NYSE:CLB ) may be sending bearish signals at...分析記事 • Jan 21
Is Core Laboratories Inc. (NYSE:CLB) Trading At A 27% Discount?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Core Laboratories fair value estimate is US$27.00 Core...分析記事 • Jan 03
Core Laboratories Inc. (NYSE:CLB) Not Lagging Market On Growth Or Pricing
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 18x, you may...分析記事 • Dec 09
Returns On Capital At Core Laboratories (NYSE:CLB) Paint A Concerning Picture
To avoid investing in a business that's in decline, there's a few financial metrics that can provide early indications...分析記事 • Nov 12
Is Core Laboratories (NYSE:CLB) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
新しいナラティブ • Sep 24
New Product Launches And Deleveraging To Propel Growth Amidst Geopolitical Challenges
Diversification in geographical markets and services strengthens revenue by expanding market presence and targeting regions with growing demand.分析記事 • Sep 19
Is Core Laboratories Inc. (NYSE:CLB) Trading At A 38% Discount?
Key Insights The projected fair value for Core Laboratories is US$29.58 based on 2 Stage Free Cash Flow to Equity...分析記事 • Aug 14
What You Can Learn From Core Laboratories Inc.'s (NYSE:CLB) P/E
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 17x, you may...分析記事 • Jul 15
We Think Core Laboratories (NYSE:CLB) Can Stay On Top Of Its Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...分析記事 • Jun 25
These Return Metrics Don't Make Core Laboratories (NYSE:CLB) Look Too Strong
To avoid investing in a business that's in decline, there's a few financial metrics that can provide early indications...分析記事 • May 02
It's Unlikely That Core Laboratories Inc.'s (NYSE:CLB) CEO Will See A Huge Pay Rise This Year
Key Insights Core Laboratories' Annual General Meeting to take place on 8th of May Salary of US$886.9k is part of CEO...分析記事 • Mar 26
Is Core Laboratories Inc. (NYSE:CLB) Trading At A 25% Discount?
Key Insights The projected fair value for Core Laboratories is US$22.93 based on 2 Stage Free Cash Flow to Equity Core...分析記事 • Mar 02
Why We're Not Concerned About Core Laboratories Inc.'s (NYSE:CLB) Share Price
Core Laboratories Inc.'s ( NYSE:CLB ) price-to-earnings (or "P/E") ratio of 19.8x might make it look like a sell right...株主還元
| CLB | US Energy Services | US 市場 | |
|---|---|---|---|
| 7D | 6.0% | -1.9% | 1.2% |
| 1Y | 29.5% | 91.6% | 28.7% |
業界別リターン: CLB過去 1 年間で91.6 % の収益を上げたUS Energy Services業界を下回りました。
リターン対市場: CLBは、過去 1 年間で28.7 % のリターンをもたらしたUSマーケットと一致しました。
価格変動
| CLB volatility | |
|---|---|
| CLB Average Weekly Movement | 7.6% |
| Energy Services Industry Average Movement | 7.2% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
安定した株価: CLB 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: CLBの 週次ボラティリティ ( 8% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 1936 | 3,300 | Larry Bruno | www.corelab.com |
Core Laboratories Inc.は、米国内外の石油・ガス業界に貯留層記述および生産向上サービスと製品を提供している。コアラボラトリーズは、貯留層分析部門と生産性向上部門を通じて事業を展開している。貯留層分析事業では、顧客の貯留層から原油や天然ガスの生産を向上させ、回収率を改善するために、石油貯留層の岩石や貯留層流体サンプルの特性評価を行う。また、原油や石油製品の特性を評価するためのラボベースの分析サービスやフィールドサービス、独自研究や共同研究、炭素回収・利用・貯留、地熱プロジェクト、採掘活動の評価・鑑定をサポートするサービスも提供している。生産性向上部門は、貯留層の坑井仕上げ、穿孔、刺激、生産、坑井放棄に関するサービスと製品を提供する。坑井仕上げの有効性を評価・監視し、石油増進回収プロジェクトの有効性を向上させるソリューションを開発するための統合診断サービスを提供している。同社は、販売代理店、技術セミナー、展示会、印刷広告、および代理店を通じて、製品のマーケティングと販売を行っている。コアラボラトリーズ社は1936年に設立され、テキサス州ヒューストンに本社を置いている。
Core Laboratories Inc. 基礎のまとめ
| CLB 基礎統計学 | |
|---|---|
| 時価総額 | US$655.49m |
| 収益（TTM） | US$29.03m |
| 売上高(TTM) | US$524.73m |
23.1x
PER（株価収益率1.3x
P/SレシオCLB は割高か？
公正価値と評価分析を参照収益と収入
| CLB 損益計算書（TTM） | |
|---|---|
| 収益 | US$524.73m |
| 売上原価 | US$420.19m |
| 売上総利益 | US$104.54m |
| その他の費用 | US$75.51m |
| 収益 | US$29.03m |
直近の収益報告
Mar 31, 2026
次回決算日
該当なし
| 一株当たり利益（EPS） | 0.63 |
| グロス・マージン | 19.92% |
| 純利益率 | 5.53% |
| 有利子負債／自己資本比率 | 41.6% |
CLB の長期的なパフォーマンスは？
過去の実績と比較を見る| Core Laboratories 配当日 | |
|---|---|
| 配当落ち日 | May 11 2026 |
| 配当支払日 | Jun 01 2026 |
| 配当落ちまでの日数 | 16 days |
| 配当支払日までの日数 | 5 days |
CLB 配当は確実ですか？
CLB 配当履歴とベンチマークを見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/26 02:06 |
| 終値 | 2026/05/26 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Core Laboratories Inc. 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。30
| アナリスト | 機関 |
|---|---|
| James West | Barclays |
| Nicholas Green | Bernstein |
| Saurabh Pant | BofA Global Research |